Target intelligence / Profile preview

UL16-binding protein 5 (ULBP5)

Target
ULBP5
Molecular classification
Other, MHC class I–related ligand (nonclassical, MIC/ULBP superfamily), NKG2D ligand (ligand for KLRK1), GPI‑anchored cell‑surface glycoprotein (ULBP family characteristic)
01

Overview

UL16-binding protein 5 (ULBP5), also known as RAET1G, is a human MHC class I–related, stress‑induced cell‑surface ligand that binds and activates the NKG2D (KLRK1) receptor on natural killer cells and subsets of T cells. It belongs to the UL16‑binding protein family identified by their interaction with the HCMV glycoprotein UL16 and the broader group of human NKG2D ligands involved in immunosurveillance of infected and malignant cells. As with other ULBPs, its expression and availability at the cell surface can be regulated by viral immune evasion (intracellular retention by HCMV UL16) and by proteolytic processing mechanisms described for related ligands, which affect NKG2D‑mediated cytotoxic responses.

Other names
Retinoic acid early transcript 1G (RAET1G)NKG2D ligand (human) family member; part of the UL16‑binding proteins (ULBPs) familyUnique long 16 binding protein 5
02

Mechanism of action

Therapies targeting this axis generally act by: - Enhancing NKG2D–ligand engagement to promote NK/T‑cell cytotoxicity - Inhibiting proteolytic shedding of NKG2D ligands (e.g., metalloprotease inhibition shown for ULBP2/MICA) to increase surface ligand density - Blocking viral immunoevasins (e.g., HCMV UL16) that retain selected NKG2D ligands intracellularly

03

Biological functions

Immune response activation via binding and activating NKG2D on NK cells and certain T cellsCo‑stimulation of cytokine production (e.g., synergizes with IL‑12 for IFN‑γ via NKG2D pathway; shown for ULBPs generally)Participation in stress‑induced immunosurveillance of infected or transformed cells as part of the NKG2D–ligand system
04

Disease associations

Cancer: NKG2D ligands are frequently expressed by tumors; ULBP family members can be shed and modulate tumor immune evasionInfection: Identified through interaction with HCMV UL16 and involved in antiviral immune recognition/evasion dynamics within the NKG2D systemPregnancy/placenta biology: ULBP1–5 are constitutively transcribed/expressed in early placenta; ULBP family implicated in trophoblast–uNK cell interactions
05

Safety considerations

On‑target immune activation: Broad enhancement of NKG2D signaling can risk off‑tumor NK/T‑cell activation and tissue damage where ligands are induced by stress or present physiologically (e.g., placenta), necessitating careful modulationLigand shedding dynamics: Metalloprotease‑mediated shedding alters efficacy and may cause systemic soluble ligands that interfere with NKG2D functions; inhibiting shedding might have complex immunological effectsViral immune evasion: Pathogen proteins (HCMV UL16) can alter ligand trafficking, complicating therapeutic strategies leveraging ULBP expression
06

Interacting drugs

None specifically approved that directly bind ULBP5 identified in the cited sources. Therapeutic agents in this axis typically target NKG2D or modulate NKG2D ligand expression/shedding; specific drug–ULBP5 interactions were not documented in these results.
07

Biomarkers

Soluble NKG2D ligands (e.g., sULBP2, sMICA) in serum as markers of tumor immune evasion and disease activityTissue expression of ULBP family members (including ULBP5 in early placenta) as contextual biomarkers in immunology of pregnancyCell‑surface ULBP expression as a biomarker for susceptibility to NKG2D‑mediated cytotoxicity in cancer/immunotherapy settings

Beyond the preview

Go deeper on UL16-binding protein 5 (ULBP5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UL16-binding protein 5 (ULBP5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call